Short Interest in Appili Therapeutics Inc. (OTCMKTS:APLIF) Expands By 785.0%

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 17,700 shares, a growth of 785.0% from the February 13th total of 2,000 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 301,300 shares, the days-to-cover ratio is presently 0.1 days.

Appili Therapeutics Trading Up 0.8 %

APLIF stock traded up $0.00 during midday trading on Wednesday, reaching $0.02. The stock had a trading volume of 70,000 shares, compared to its average volume of 87,680. The company’s fifty day simple moving average is $0.02 and its 200 day simple moving average is $0.02. Appili Therapeutics has a 52-week low of $0.01 and a 52-week high of $0.05. The company has a market cap of $2.95 million, a price-to-earnings ratio of -1.22 and a beta of -0.55.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.